Latest Headlines
-
SwRI Develops Chemistry LLM Called GAMES For Faster Drug Discovery
8/14/2025
Southwest Research Institute scientists and engineers have developed a custom large language model (LLM) to accelerate drug design and discovery.
-
Immunotherapy Drug Eliminates Aggressive Cancers In Clinical Trial
8/14/2025
Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment. While effective at activating the immune system to kill cancer cells in animal models, the drugs had limited impact on patients in clinical trials and caused dangerously systemic inflammatory responses, low platelet counts, and liver toxicity, among other adverse reactions—even at a low dose.
-
Polaris Quantum Biotech Unveils QuADD: Next-Generation Quantum-AI Drug Discovery Platform - Beta Testers Wanted
8/12/2025
Polaris Quantum Biotech (PolarisQB), a leader in quantum-powered life science solutions, today announced the official launch of QuADD (Quantum-Aided Drug Design), the world’s first SaaS platform harnessing quantum computing and artificial intelligence to revolutionize drug discovery.
-
KAIST Develops AI That Automatically Designs Optimal Drug Candidates For Cancer-Targeting Mutations
8/12/2025
Traditional drug development methods involve identifying a target protin (e.g., a cancer cell receptor) that causes disease, and then searching through countless molecular candidates (potential drugs) that could bind to that protein and block its function.
-
Bayer And Kumquat Biosciences Enter Global Exclusive License And Collaboration In Precision Oncology
8/12/2025
Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor.
-
HopeAI Joins Mayo Clinic Platform To Transform The Future Of Drug Development With AI
8/12/2025
HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined the prestigious Mayo Clinic Platform Accelerate program.
-
Garden Launches BLOOM To Make AI Drug Design IP-Aware In Real Time
8/11/2025
Garden today announced BLOOM (Branching Lookup Optimized for Organic Molecules), a Markush structure search engine that gives AI drug-design teams near-instant verification of small-molecule IP landscapes, so researchers can iterate on candidates with legal certainty built into the loop.
-
AMI Pharm Advances AYP-101 To Phase 3, Paving The Way For A New Era In Fat-Reduction Injectable Drugs
8/11/2025
AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fat (commonly known as a "double chin").
-
Researchers Discover All-New Antifungal Drug Candidate In McMaster's Greenhouse
8/11/2025
A research team at McMaster University has discovered a new drug class that could someday lead to breakthrough treatments for dangerous fungal infections.
-
New Cancer Drug Boosts Effectiveness Of Chemotherapy – Even In Resistant Tumours
8/11/2025
A groundbreaking cancer drug could enhance how patients respond to chemotherapy even in treatment-resistant tumours.